JO
CERE

John Overdeck’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

John Overdeck’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,700
Closed -$833K – 3429
2024
Q1 		$833K Hold
19,700
– – ﹤0.01% 2065
2023
Q4 		$835K Sell
19,700
-4,300
-18% -$124K ﹤0.01% 2179
2023
Q3 		$524K Sell
24,000
-8,300
-26% -$208K ﹤0.01% 2254
2023
Q2 		$1.03M Buy
32,300
+18,600
+136% +$571K ﹤0.01% 1931
2023
Q1 		$334K Buy
13,700
+5,700
+71% +$167K ﹤0.01% 2374
2022
Q4 		$252K Buy
+8,000
New +$226K ﹤0.01% 2309

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

John Overdeck's CERE Position: Q2 2024 in Review

John Overdeck sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 19,700 shares — an estimated $833K sold.

John Overdeck first reported a position in CERE in Q4 2022 and held it in 6 quarters. The position peaked at $1.03M in Q2 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • John Overdeck reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • John Overdeck sold 19,700 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $833K.
  • John Overdeck first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
  • John Overdeck's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.03M in Q2 2023.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.